10x Genomics Inc - Ordinary Shares - Class A Stock News

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will inco...

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences,...

PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the second quarter ended June 30, 2026.

Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platforms PLEASANTON, Calif., July 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Lausanne University Ho...

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a n...

Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutio...

10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.